INSTINCT BIO TECHNICAL CO HO
BIOTNASDAQTrading Snapshot
- Day Range
- $0.34 – $0.35
- 52-Week Range
- $2.00 – $19.00
- Volume
- $3.62B
- Avg Volume
- $3.66B
- Shares Outstanding
- 28.8M
- Next Earnings
- Nov 6, 2026
Fundamentals Snapshot
- Annual Revenue
- $714,237
- Last Q Revenue
- $163,706
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.18
- Dividend Yield
- —
Why Investors Own BIOT
- ✓High-growth profile — revenue up -9.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 26% gross margin and 26% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INSTINCT BIO TECHNICAL CO HO
BIOT
StockOtter · stockotter.spaceAbout INSTINCT BIO TECHNICAL CO HO
An integrated regenerative medicine and longevity company focused on the research, manufacturing, and commercialization of regenerative health technologies, stem cell-derived products, wellness solutions, and advanced skincare.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
NEW YORK and TOKYO, Sept. 04, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC.
Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
NEW YORK and TOKYO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (Nasdaq: BIOT) ("Instinct Bio" or the "Company") today announced a cooperation agreement with PT PARVA CANDELA ("PARVA"),
BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
NEW YORK and TOKYO, July 29, 2026 (GLOBE NEWSWIRE) -- INSTINCT BIO TECHNICAL COMPANY HOLDINGS INC. (NASDAQ: BIOT) ("Instinct Bio" or the "Company") today announced its decision to bring its own Japanese aesthetic healthc
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia's Fastest-Growing Aesthetics Markets
BIOT to Launch Indonesia's First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” Building a Recurring-Revenue Platform
Instinct Bio (Nasdaq: BIOT) Secures $150 Million Equity Funding to Advance Regenerative Medicine Platform and Strategic Growth
Transformative funding agreement equips Instinct Bio with discretionary capital to scale its longevity-focused ecosystem and capture market opportunities. Transformative funding agreement equips Instinct Bio with discret